FOSUN PHARMA (02196): Approval for Deferasirox Tablets and Granules Registration

Stock News

Oct 24

FOSUN PHARMA (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Deferasirox tablets and granules (hereinafter referred to as “the drugs”). These drugs are independently developed chemical drugs by the group (the company and its subsidiaries). The approved indications include treatment for (1) chronic iron overload in β-thalassemia patients above 2 years old due to frequent blood transfusions, and (2) chronic iron overload in non-transfusion-dependent thalassemia syndrome patients aged 10 years and above. As of September 2025, the group has invested approximately RMB 24.55 million (unaudited) in research and development for these drugs. According to the latest IQVIA CHPA data, the sales revenue of Deferasirox formulations in mainland China (excluding Hong Kong, Macau, and Taiwan) is expected to be approximately RMB 128 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1194949057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194949057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194949057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194949057","market":"sg","top_or_hot":-1,"title":"FOSUN PHARMA (02196): Approval for Deferasirox Tablets and Granules Registration","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Deferasirox tablets and granules (hereinafter referred to as “the drugs”). These drugs are independently developed chemical drugs by the group (the company and its subsidiaries). The approved indications include treatment for (1) chronic iron overload in β-thalassemia patients above 2 years old due to frequent blood transfusions, and (2) chronic iron overload in non-transfusion-dependent thalassemia syndrome patients aged 10 years and above. As of September 2025, the group has invested approximately RMB 24.55 million (unaudited) in research and development for these drugs. According to the latest IQVIA CHPA data, the sales revenue of Deferasirox formulations in mainland China (excluding Hong Kong, Macau, and Taiwan) is expected to be approximately RMB 128 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (02196): Approval for Deferasirox Tablets and Granules Registration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (02196): Approval for Deferasirox Tablets and Granules Registration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-24 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Deferasirox tablets and granules (hereinafter referred to as “the drugs”). These drugs are independently developed chemical drugs by the group (the company and its subsidiaries). The approved indications include treatment for (1) chronic iron overload in β-thalassemia patients above 2 years old due to frequent blood transfusions, and (2) chronic iron overload in non-transfusion-dependent thalassemia syndrome patients aged 10 years and above. As of September 2025, the group has invested approximately RMB 24.55 million (unaudited) in research and development for these drugs. According to the latest IQVIA CHPA data, the sales revenue of Deferasirox formulations in mainland China (excluding Hong Kong, Macau, and Taiwan) is expected to be approximately RMB 128 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1194949057","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194949057","pubTimestamp":1761302797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for the drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0188":"融资融券","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","02196":"复星医药","BK0096":"民营医院","BK1515":"抗疫概念","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","BK1191":"制药"},"translate_title":"复星医药(02196)：地拉罗司片剂和颗粒注册获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Deferasirox tablets and granules (hereinafter referred to as “the drugs”). These drugs are independently developed chemical drugs by the group (the company and its subsidiaries). The approved indications include treatment for (1) chronic iron overload in β-thalassemia patients above 2 years old due to frequent blood transfusions, and (2) chronic iron overload in non-transfusion-dependent thalassemia syndrome patients aged 10 years and above. As of September 2025, the group has invested approximately RMB 24.55 million (unaudited) in research and development for these drugs. According to the latest IQVIA CHPA data, the sales revenue of Deferasirox formulations in mainland China (excluding Hong Kong, Macau, and Taiwan) is expected to be approximately RMB 128 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}